TAFA chemokine like family member 4Genealiases: FAM19A4 · TAFA-4
Q-omics provides the consensus-scored TAFA4 profile across patient tissues and cancer cell-line models. TAFA4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TAFA4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TAFA4 RNA expression shows 13,777 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where TAFA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAFA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAFA4 survival associations across molecular data types. TAFA4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAFA4 RNA expression–survival associations across cancer types. High TAFA4 expression shows unfavorable associations in UCEC, KIRP, ACC and UVM, but favorable associations in DLBC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TAFA4 RNA expression.
This table summarizes TAFA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TAFA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAFA4 shows lower tumor expression in KIRC, KICH, COAD, THCA, STAD and KIRP. The KIRC box plot shows higher TAFA4 RNA expression in normal versus tumor tissue (log2 FC = −0.474, t-test p < 0.001).
This table shows molecular features associated with TAFA4 in patient tissues and cancer cell lines. In patient samples, TAFA4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAFA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUSC.
